Clinsys Redefines Resource Services with the Launch of Clinsys ALTERNA
Clinsys Clinical Researchannounced the launch of Clinsys ALTERNA for customized Phase I–IV alternative solutions.
Bedminster, NJ-April 10, 2008-Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of Clinsys ALTERNA, which utilizes its Global Project Solution® (Clinsys GPS®) to augment clinical resource services. The new division demonstrates Clinsys’ commitment to aligning its service offerings with its sponsors’ and the life sciences industry’s continuously evolving staffing needs.
Clinsys ALTERNA provides customized Phase I–IV clinical trial alternative solutions to the conventional outsourcing model. The division is a core element of Clinsys GPS, a unique, highly effective, and proven integrated project management solution that brings the sponsor and the Clinsys project teams together to collaborate and agree on all aspects of the clinical study-before, during, and after-to ensure the project’s success.
“Clinsys ALTERNA provides a targeted and flexible clinical resourcing model that adapts to best serve a sponsor’s trial management needs,” said David E. Williams, chief executive officer of Clinsys. “We devoted the time and energy required to approach the evolution of resourcing in an innovative way that both maximizes efficiencies and decreases deliverable timelines.”
Drawing on extensive clinical research experience, Clinsys ALTERNA delivers a custom-designed, time-sensitive clinical solution that enables sponsors to engage its services in site management, clinical monitoring, project management, drug safety, regulatory, and medical writing on a contract basis. Clinsys ALTERNA combines therapeutic expertise, clinical screening, performance reviews, site references, and global reach to offer clients the most dependable and comprehensive alternative approach to their trial needs. Visit clinsysalterna.com for more information.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
